October marks National ADHD Awareness Month, dedicated to education and reducing misconceptions about attention-deficit/hyperactivity disorder (ADHD). This year’s theme, “Awareness is Key!” emphasizes the importance of informed understanding. Organizations such as the ADHD Awareness Month Coalition, CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) and ADDA (Attention Deficit Disorder Association) actively provide expert insights to support individuals living with ADHD and their families.
In the US, around 7 million children aged three to 17 in the US have been diagnosed with ADHD, with boys (15 percent) more likely to be diagnosed than girls (eight percent).
ADHD often coexists with other conditions; nearly 78 percent of these children also have an additional mental or behavioral disorder. Children with ADHD also face higher annual healthcare costs, ranging from $722 to $11,555, with indirect costs, such as parental productivity loss, further adding to the economic burden.
Amidst these challenges, new developments and treatments are offering hope and improving management options for those affected by ADHD.
XTALKS WEBINAR: Accelerating Psychiatry Clinical Trials Through a Patient-Centric Approach: Real Patients, Real Outcomes
Live and On-Demand: Wednesday, October 30, 2024, at 10am EDT (3pm CET/EU-Central)
Register for this free webinar to explore steps for improving psychiatry trials, including recognizing the complexity of the population in protocol and trial design, and understanding the patient journey to optimize recruitment and retention.
Recent Developments in ADHD Management
Recent US Food and Drug Administration (FDA) approvals are reshaping ADHD treatments. In May 2024, Tris Pharma secured FDA approval for Onyda XR (clonidine hydrochloride), the first liquid non-stimulant ADHD medication with nighttime dosing. Onyda XR is now available in the US and is meant for children six and older, either on its own or in combination with other approved medications. This once-daily medication serves as an alternative for patients who may not respond to stimulants or experience side effects.
June 2024 saw the FDA clearance of Akili’s EndeavorOTC, the first over-the-counter (OTC) digital therapeutic for adults with ADHD. This engaging video game-based intervention is designed to improve attention function in adults aged 18 and older with primarily inattentive or combined-type ADHD. Available on the Apple App Store and Google Play Store, this digital therapeutic offers a non-pharmacological alternative to help manage ADHD.
Another significant development came in July 2024, as Qbtech, a leader in objective ADHD testing, launched a $4 million initiative providing free FDA-cleared testing for former patients of the telehealth company Done, following concerns over stimulant prescription practices. This move reinforces the importance of objective, evidence-based assessments, particularly in telehealth.
August brought the launch of Quillivant ER Oral Suspension in Canada, marking the first extended-release (ER) liquid methylphenidate approved by Health Canada. Designed for children aged six to 12, this banana-flavored liquid acts quickly (within 45 minutes) and maintains symptom control for up to 12 hours. The innovative LiquiXR technology developed by Tris Pharma allows for flexible dosing and convenience, ensuring effective treatment for pediatric ADHD.
Samsung Canada also expanded its partnership with the Possibilities Clinic, introducing the SmartStudy resource hub on Samsung’s SmartThings platform. The hub supports students with ADHD through tech solutions for managing daily tasks, offering tips, routines and playlists aimed at boosting productivity and focus. With the SmartThings app, students can automate routines, minimize distractions and enhance creativity.
Empowering ADHD on National ADHD Awareness Month 2024
This year, initiatives that focus on empowering the ADHD community have gained significant traction. ADDitude magazine has launched “ADHD Empowerment Month,” moving beyond awareness to celebrate the creativity, resilience and strengths within the ADHD community. Through daily community-driven definitions and profiles of influential figures, the campaign reshapes the conversation around ADHD.
Similarly, in July, Understood.org introduced “MissUnderstood,” a podcast channel dedicated to women with ADHD. The podcast features candid conversations, expert perspectives and practical tips to support and uplift women navigating ADHD. This initiative aims to promote understanding of the unique experiences faced by women.
Addressing ADHD Medication Shortages
While recent advancements in ADHD treatments have been encouraging, medication shortages in the US continue to impact patients. The FDA notes some improvement, yet certain medications remain hard to find. To address this, the US Drug Enforcement Administration recently increased the production limit for Takeda’s Vyvanse (lisdexamfetamine) and its generics by 24 percent. This move, along with efforts by other manufacturers, aims to alleviate supply gaps. Additional doses from new suppliers are expected in the coming months to help meet ongoing demand.
Join or login to leave a comment
JOIN LOGIN